Citeline's expert analysts regularly produce reports on key aspects of the industry, new therapy developments and trends. Enjoy free access to these insights by downloading our latest whitepapers below.
A review of the current landscape of HIV vaccine research for prevention and treatment, to determine if the field has rebounded from the setbacks of the STEP and ORVACS 002 trials. Trends in prophylactic and therapeutic vaccine clinical research are also revealed. Is gene therapy research a potential alternative to a therapeutic vaccine?Download
A profile of the drugs and clinical trials making up the current SLE landscape. How is Benlysta shaping the future of SLE drug development and providing a window onto the continued unmet need for many patients suffering from this diverse disease?
Rising to the Challenge:An Analysis of the Influenza Vaccine Landscape in Response to the Swine Flu Pandemic
Citeline evaluates the methods manufacturers pursued in response to the swine flu pandemic, with an analysis of alternate manufacturing methods and routes of administration. Have the major players in influenza vaccines shifted?
Citeline examines the clinical trials activity for MS looking to discern any trends or paradigm shifts that reflect the patient segments being investigated.Download
Immunotherapeutic drugs took center stage this year at The 49th Annual ASCO Meeting. This report provides an overview of the trials reported, looks at some of the individual drug highlights and analyses the distribution of investigators in those trials.Download
Citeline explores the current drug development landscape, the mechanisms of action, biomarkers, and top sponsors that are shaping Alzheimer’s treatment into the next three years.Download
Citeline analyzes benchmark data for oncology trials whose protocols include or omit objectives of identifying prognostic or predictive biomarkers, or endpoints involving biomarkers to assess efficacy or toxicity.Download
Cardiovascular safety is a critical factor in T2D new drug research. This report outlines the mixed successes sponsors have had while navigating new FDA requirements.Download
An analysis of Phase III hepatitis C virus infection (HCV) industry-sponsored clinical trials from the perspective of investigator utilization. Are sponsors recruiting more sites globally to enroll a smaller average of patients per sites?Download
A geographic analysis of industry-sponsored cancer trials shows how to use investigator distribution trends to compare to potential trial-launch locations in order to access one's patient population of interest and sharpen feasibility estimates.Download
Citeline examines clinical trial timelines in oncology, and a cross-section of trials involving targeted therapies, revealing an overall trend toward decreases in trial durations – enrollment period and treatment period.Download
Citeline examines over 4,300 industry-sponsored Phase II and Phase III clinical trials across multiple therapeutic areas and reveals a surprising trend reversal in the length of trial enrollment periods and total trial durations.Download
Citeline Associate Director Dr. Fern Barkalow looks at the top countries, companies and diseases involved in biosimilar mAb development. The report also provides an overview of recent industry collaborations in this area of research.Download
The Citeline Analytics team outlines key findings from an analysis of clinical trial outcomes in six therapeutic areas and begins to explore the notion of how historical records can be used as predictors or benchmarks of future performance.Download